These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 25398692)

  • 21. Deoxyshikonin isolated from
    Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
    Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
    [No Abstract]   [Full Text] [Related]  

  • 22. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
    Eum KH; Ahn SK; Kang H; Lee M
    Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
    Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S; Wang Q; Feng M; Li J; Guan Z; An D; Dong M; Peng Y; Kuerban K; Ye L
    Appl Microbiol Biotechnol; 2017 Feb; 101(4):1535-1546. PubMed ID: 27807662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
    J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RETRACTED ARTICLE: Investigating EGFR-VEGF-mediated apoptotic effect of cucurbitacin D and I combination with sorafenib via Ras/Raf/MEK/ERK and PI3K/Akt signaling pathways.
    Üremis N; Türköz Y; Üremiş MM; Çiğremiş Y; Şalva E
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3247. PubMed ID: 37917368
    [No Abstract]   [Full Text] [Related]  

  • 29. Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
    Meng Y; Lin ZM; Ge N; Zhang DL; Huang J; Kong F
    Am J Chin Med; 2015; 43(7):1471-86. PubMed ID: 26503559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycotoxin verrucarin A inhibits proliferation and induces apoptosis in prostate cancer cells by inhibiting prosurvival Akt/NF-kB/mTOR signaling.
    Liu Y; Gao X; Deeb D; Zhang Y; Shaw J; Valeriote FA; Gautam SC
    J Exp Ther Oncol; 2016 Nov; 11(4):251-260. PubMed ID: 27849335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.
    Alonso N; Diaz Nebreda A; Monczor F; Gutkind JS; Davio C; Fernandez N; Shayo C
    Biochim Biophys Acta; 2016 Sep; 1860(9):1998-2007. PubMed ID: 27316323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
    Ricciardi MR; Scerpa MC; Bergamo P; Ciuffreda L; Petrucci MT; Chiaretti S; Tavolaro S; Mascolo MG; Abrams SL; Steelman LS; Tsao T; Marchetti A; Konopleva M; Del Bufalo D; Cognetti F; Foà R; Andreeff M; McCubrey JA; Tafuri A; Milella M
    J Mol Med (Berl); 2012 Oct; 90(10):1133-44. PubMed ID: 22399013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.
    Chen Y; Zheng L; Liu J; Zhou Z; Cao X; Lv X; Chen F
    Int Immunopharmacol; 2014 Aug; 21(2):447-55. PubMed ID: 24905636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    Du W; Zhou JR; Wang DL; Gong K; Zhang QJ
    World J Surg Oncol; 2012 Apr; 10():60. PubMed ID: 22520038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.